Virginia Retirement Systems ET AL Has $1.46 Million Holdings in Puma Biotechnology Inc (PBYI)

Virginia Retirement Systems ET AL raised its stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 121.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,200 shares of the biopharmaceutical company’s stock after purchasing an additional 6,700 shares during the period. Virginia Retirement Systems ET AL’s holdings in Puma Biotechnology were worth $1,461,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PBYI. Schwab Charles Investment Management Inc. grew its holdings in Puma Biotechnology by 5.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 119,312 shares of the biopharmaceutical company’s stock valued at $4,439,000 after purchasing an additional 6,138 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after acquiring an additional 97 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Puma Biotechnology in the second quarter worth $2,026,000. Strs Ohio acquired a new stake in shares of Puma Biotechnology in the second quarter worth $122,000. Finally, Rothschild Asset Management Inc. grew its stake in shares of Puma Biotechnology by 40.7% in the second quarter. Rothschild Asset Management Inc. now owns 33,404 shares of the biopharmaceutical company’s stock worth $2,920,000 after acquiring an additional 9,658 shares during the last quarter. Institutional investors own 96.05% of the company’s stock.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares in the company, valued at $5,068,680. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The disclosure for this sale can be found here. 21.10% of the stock is owned by insiders.

Shares of Puma Biotechnology Inc (NASDAQ PBYI) opened at $98.05 on Thursday. Puma Biotechnology Inc has a 52 week low of $28.35 and a 52 week high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the prior year, the firm earned ($1.11) EPS. equities research analysts anticipate that Puma Biotechnology Inc will post -8.19 earnings per share for the current year.

Several equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 14th. Credit Suisse Group raised their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Barclays restated a “buy” rating and issued a $122.00 price objective (up previously from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. Citigroup raised their price objective on shares of Puma Biotechnology from $156.00 to $164.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. Finally, Royal Bank Of Canada lowered their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $130.67.

WARNING: “Virginia Retirement Systems ET AL Has $1.46 Million Holdings in Puma Biotechnology Inc (PBYI)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/12/07/virginia-retirement-systems-et-al-has-1-46-million-holdings-in-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit